Cyclosporin depresses pancreatic islet expression of antigens for islet cell autoantibodies in non obese diabetic mice

Journal of Autoimmunity

Volumn 9, Issue 1, 1996, Pages 29-39

  El Mansour, A ^a   Martignat, L ^a   Maugendre, S ^b   Senecat, O ^a   Gouin, E ^a   Saï, Pierre ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b University School of Medicine   (France)

Author keywords

Cyclosporin; Diabetes; Islet cell autoantibodies; NOD mice

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE; PANCREAS ISLET CELL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0029940717     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0005     Document Type: Article

References (63)

1. Makino S., Kinomoto K., Muraoka Y., Mitzushima Y., Katagiri K., Tochino Y. 1980. Breeding of a non obsese diabetic strain of mice. Exp. Anim. (Tokyo) 29: 1-13
2. Castano L., Eisenbarth G.S. 1990. Type 1 diabetes: a chronic autoimmune disease of man, mouse and rat. Annu. Rev. Immunol. 8: 647-79
3. Bowman M.A., Leiter E.H., Atkinson M.A. 1994. Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol. Today 15: 115-120
4. Gotfredsen C., Buschard K., Frandsen E.K. 1985. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28: 933-935
5. Atkinson M.A., MacLaren N.K., Luchetta R. 1990. Insulitis and diabetes in NOD mice are reduced by prophylactic insulin therapy. Diabetes 39: 933-937
6. Keller R.J., Eisenbarth G.S., Jackson R.A. 1993. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 341: 927-928
7. Vlahos W.D., Yale J.F. 1987. Prevention of type 1 diabetes in the BB rat by diazoxide. Clin. Invest. Med. 10: B65 (Abstract)
8. Borel J.F. 1989. Pharmacology of cyclosporin (sandimmune). 4 Pharmacological properties in vivo. Pharmacol. Rev. 41: 259-371
9. Shevach E.M. 1985. The effects of cyclosporin A on the immune system. Annu. Rev. Immunol. 3: 397-423
10. Feutren G., Assan R., Karsenty G., et al. 1986. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a Multicentre Double-blind Trial. Lancet 2: 119-123
11. Mori Y., Suko M., Okudaira H., et al. 1986. Preventive effects of cyclosporin on diabetes in NOD mice. Diabetologia 29: 244-247
12. Laupacis A., Stiller C.R., Gardell C., et al. 1983. Cyclosporin prevents diabetes in BB Wistar rats. Lancet 1: 10-12
13. Like A.A., Dirodi V., Thomas S., et al. 1984. Prevention of diabetes mellitus in the BB/W rat with cyclosporin. A. Am. J. Pathol. 117: 92-97
14. Prud'homme G.J., Parfrey W.A., Vannier L.E. 1981. Cyclosporin-induced autoimmunity and hyperactivity. Autimmunity 9: 345-348
15. Jaworski M.A., Jewell L., Honore L. 1985. Induction of insulin-dependent diabetes mellitus in diabetes-resistant lines of BB rats. (Abstract) Diabetes 34 (supplt 1): 72A
16. Saï P., Senecat O., Martignat L., Gouin E. 1994. Enhancement of diabetes in NOD mice by neonatal injections of Cyclosporin A. Clin. Exp. Immunol. 97: 138-144
17. Sakaguchi S., Sakaguchi N. 1989. Organ-specific autoimmune disease induced in mice by elimination of T cell subsets. Neonatal administration of cyclosporin A causes autoimmune disease. J. Immunol. 142: 471-480
18. Kolb H., Oschilewski M., Scwab E., Oschilewski U., Kiesel U. 1985. Effect of cyclosporin A on low-dose streptozotocin diabetes in mice. Diabetes Research 2: 191-193
19. Sai P., Sestier C., Odent S., et al. 1985. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol. Letters 10: 57-60
20. Sai P., Maugendre D., Loréal O., et al. 1988. Effects of Cyclosporin on autoimmune diabetes induced in mice by streptozotocin: β cell toxicity and rebound of insulitis after cessation of treatment. Diab. Metab. 14: 455-462
21. Yale J.F., Roy R.D., Grose M., Seemayer T.A., Murphy G.E, Marliss E.B. 1985. Effects of cyclosporin on glucose tolerance in the rat. Diabetes 34: 1309-1313
22. Hann H.J., Dunger A., Laube F., Besch W., Radloff E., Kavert C., Kotzke G. 1986. Reversibility of the acute toxic effects or cyclosporin A on pancreatic β cells or wistar rats. Diabetologia 29: 489-494
23. Gunnarson R., Klintmalm G., Lundgren G., Wilczek A., Ostman J., Groth C.G. 1983. Deterioration in glucose metabolism in pancreatic transplant recipients given cyclosporin. Lancet 2: 571-572
24. Andersson A., Borg H., Hallberg A., Hellerström C., Sandler S., Schnell A. 1984. Long-term effects of cyclosporin A on cultured mouse pancreatic islets. Diabetologia 27: 66-69
25. Helmchen U., Schmidt W.E., Seigel E.G., Creutzfelt W. 1984. Morphological and functional changes of pancreatic β cells in cyclosporin A-treated rats. Diabetologia 27: 416-418
26. Nielsen J.H., Mandrup-Poulsen T., Nerup J. 1986. Direct effects of cyclosporin A on human pancreatic β cells. Diabetes 35: 1049-1052
27. Robertson R.P. 1986. Cyclosporin-induced inhibition of insulin secretion in isolated rat islets and HIT cells. Diabetes 35: 1016-109
28. Saï P., Elmansour A., Audrain M., Charbonnel B., Bardet S. 1993. Quantification of human cytoplasmic islet cell autoantibodies which crossreact with mouse islets: a follow-up study in type 1 diabetic patients and in first degree relatives. Diabetologia 36: 774-784
29. Chaillous L., Delamaire M., Elmansour A., Maugendre D., Rohmer V., Joseph M.G., Lecomte P., Limal J.M., Charbonnel B., Allannic H., Saï P. 1994. Combined analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 islet protein, and antibodies to glutamate decarboxylase in subjects at risk for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 37: 491-497
30. Chaillous L., Delamaire M., Maugendre D., Marre M., Charbonnel B., Allannic H., Saï P. 1994. Analysis of islet cell antibodies which cross-react with mouse pancreas, antibodies to the Mr 64,000 protein, and antibodies to intact glutamate decarboxylase, in Type 1 diabetic patients. Diabetes Care 17: 115-1123
31. Martignat L., El Mansour A., Audrain M., Julien J.F., Charbonnel B., Saï P. 1995. Pancreatic expression of antigens for islet cell antibodies in non-obese diabetic mice. Journal of Autoimmunity 8: 465-482
32. Senecat O., Martignat L., El Mansour A., Audrain M., Julien J.F., Saï P. 1994. Diabetes enhancement and increased islet antigen expression in NOD mice following neonatal injections of glucose and arginine. Metabolism clinical and experimental 43: 1-10
33. Marshall M.O., Hoyer P.E., Petersen J.S., Hejnaes K.R., Genovese S., Dyrberg T., Bottazzo G.F. 1994. Contribution of glutamate decarboxylase antibodies to the reactivity of islet cell cytoplasmic antibodies. Journal of Autoimmunity 7: 497-508
34. Genovese S., Bonifacio E., Dean B.M., McNally J., Bosi E., Bottazzo G.F. 1992. Distinct cytoplasmic islet cell antibodies with different risk of type 1 (insulin dependent) diabetes mellitus. Diabetologia 35: 385-388
35. Gianani R., Pugliese A., Bonner-Weir S. 1992. Pronostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type 1 diabetes. Diabetes 41: 347-353
36. Atkinson M.A., Kaufman D.L., Newman D., Tobin A.J., Maclaren N.K. 1993. Islet cell cytoplasmic antibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J. Clin. Invest. 91: 350-356
37. Timsit J., Caillat-Zucman S., Blondel H., Bach J.F., Boitard C. 1992. Islet cell antibody heterogeneity among Type 1 (insulin-dependent) diabetic patients. Diabetologia 35: 792-795
38. Nayac R.C., Omar M.A.K., Rabizadeh A., Srikanta S., Eisenbarth G.S. 1985. 'Cytoplasmic' islet cell antibodies: evidence that the target antigen is a sialoglycoconjugate. Diabetes 34: 617-619
39. Colman P.G., Nayak R.C., Campbell I.L., Eisenbarth G.S. 1988. Binding of cytoplasmic islet cell antibodies is blocked by human pancreatic glycolipid extracts. Diabetes 37: 645-652
40. Karlsen A.E., Hagopian W.A., Petersen J.S., Boel E., Dyrberg T., Grabin C.E., Michelsen B.K., Madsen O.D., Lernmark A. 1992. Recombinant Glutamic Acid Decarboxylase (representing the singler isoform expressed in human islets) detects IDDM-associated 64,000 Mr autoantibodies. Diabetes 41: 1355-1359
41. Velloso L.A., Kämpe O., Eizirik D.L., Hallberg A., Anderson A., Karlsson F.A. 1993. Human autoantibodies react with glutamic acid decarboxylase antigens in human and in rat but not in mouse islets. Diabetologia 36: 39-46
42. Velloso L.A., Kämpe O., Hallberg A., Christmanson L., Betsholtz C., Karlsson F.A. 1993. Demonstration of GAD65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression. J. Clin. Invest. 91: 2084-2090
43. Petersen J.S., Russel S., Marshall M.O., Kofod H., Buschard K., Cambon N., Karlsen A.R., Boel E., Hagopian W.A., Hejnaes K.R., Moody A., Dyrberg T., Lernmark A., Madsen O.D., Michelsen B.K. 1993. Differential expression of glutamic acid decarboxylase in rat and human islets. Diabetes 42: 484-495
44. Kim J., Richter W., Aanstoot H.J., Shi Y., Pu Q., Rajotte R., Warnock G., Baekkeskov S. 1993. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes 42: 1799-1808
45. Baekkeskov S., Aanstoot H.K., Christgau S., Reetz A., Solimena M., Cascalho M., Folli F., Richter-Olesen, De Camilli P. 1990. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347: 151-156
46. Kaufman D.L., Erlander M.G., Clare-Satzler M., Atkinson M.A., Maclaren N.K., Tobin A.J. 1992. Autoimmunity to two forms of glutamate decarboxylase in insulin dependent diabetes mellitus. J. Clin. Invest. 89: 283-292
47. Tisch R., Yang X.D., Singer S.M., Liblau R.S., Fugger L., McDevitt H.O. 1993. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 366: 72-75
48. Atkinson M.A., Kaufman D., Campbell L., Gibbs K.A., Shah S.C., Bu D.F., Erlander M.G., Tobin A.J., Maclaren N.K. 1992. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 339: 458-459
49. Dias J.L., Ways J., Hammonds P. 1993. T-lymphocyte lines specific for glutamic acid decarboxylase (GAD) the 64K β cell antigen of IDDM. Diabetes 41: 118-121
50. Honeyman M.C., Cram D.S., Harrison L.C. 1993. Glutamic acid decarboxylase 67-reactive T cells. A marker of insulin-dependent diabetes. J. Exp. Med. 177: 535-540
51. Kaufman D.L., Clare-Satzler M., Tian J., Forsthuber T., Tiug G.S.P., Robinson P., Atkinson M.A., Sercarz E.E., Tobin A.J., Lehmann P.V. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69-72
52. Kaufman D.L., Houser C.R., Tobin A.L. 1991. Two forms of the γ-aminobutyric acid synthetic enzyme glytamate decarboxylase have distinct intraneuronal distributions and cofactor interactions. Journal of Neurochemistry 56: 720-723
53. Appel M.C., Dotta F., O'Neill J.J., Eisenbarth G.S. 1989. β cell activity regulates the expression of islet antigenic determinants. Diabetologia 32: A461 (Abstract), 1989
54. Kämpe O., Anderson A., Björk E., Hallberg A., Karlsson F.A. 1990. High-glucose stimulation of 64,000 Mr Islet cell autoantigen expression. Diabetes 38: 1326-1328
55. Björk E., Kämpe O., Anderson A., Karlsson F.A. 1992. Expression of the 64KDa/glutamic acid decarboxylase rat islet cell autoantigen is influenced by the rate of insulin secretion. Diabetologia 32: 490-493
56. Imboden J.B., Stobo I.B. 1985. Transmembrane signalling by the T-cells antigen receptor perturbation of the T3 antigen receptor complex generates inositol phosphates and release calcium ions from intracellular stores. J. Exp. Med. 161: 446-448
57. Schreiber S.L., Crabtree G.R. 1992. The mechanism of action of cyclosporin A and FK506. Immunology Today 13: 136-142
58. Colombani P.M., Robb A., Hess A.D. 1985. Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes. Science 9: 228-337
59. Gao E.K., Lo D., Cheney R., et al. 1988. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 336: 176-179
60. Jenkins M.K., Schwartz R.H., Pardoll D.M. 1988. Effects of cyclosporine A on T cell development and clonal deletion. Science 241: 1655-1658
61. Miller J.F.A.P., Morahan G. 1992. Peripheral T cell tolerance. Ann. Rev. Immunol. 10: 51-70
62. Taguchi O., Nishizuka Y. 1987. Self tolerance and localized autoimmunity: mouse models of autoimmune disease that suggest that tissue-specific suppressor cells are involved in self tolerance. J. Exp. Med. 65: 146-56
63. Webb S., Morris C., Sprent J. 1970. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63: 1249-1256